Chargement en cours...
The molecular basis of pharmacological chaperoning in human α-galactosidase
Fabry disease patients show a deficiency in the activity of the lysosomal enzyme α-galactosidase (α-GAL or α-Gal A). One proposed treatment for Fabry disease is pharmacological chaperone therapy, where a small molecule stabilizes the α-GAL protein, leading to increased enzymatic activity. Using enzy...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2011
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3246215/ https://ncbi.nlm.nih.gov/pubmed/22195554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chembiol.2011.10.012 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|